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Introduction 
Bladder cancer is the 9th most common cancer diagnosis 
worldwide, with more than 330,000 new cases each year and more 
than 130,000 deaths per year, with an estimated male:female ratio of 
3.8:1.0 In industrialized Western countries, transitional cell tumors 
comprise 90%-95% of bladder tumors; 3%-7% are squamous cell, 
and 1%-2% are adenocarcinomas.1–3 In developing countries in 
certain locations, up to 75% of cases are squamous cell carcinomas 
associated with Schistosoma haematobium infestation.2 In Egypt, 
bladder cancer has been the most common cancer during the past 50 
years. Previous research has reported a significant decrease in SCC 
in Egypt, although the overall bladder cancer incidence in Egypt has 
remained steady due to an increase in TCC over the past 30 years.4–6 
Over the last few decades, there have been advances in urinary bladder 
cancer management leading to earlier detection of the disease and the 
development of more effective treatments, improving the outcomes 
for people living with the disease and resulting in declines in urinary 
bladder cancer deaths.7–9 However, recent studies in molecular biology 
and genetics have identified survivin as a candidate gene responsible 
for cancer progression.10
Survivin, a unique and the smallest member of the Inhibitor of 
Apoptosis (IAP) family, also called baculoviral inhibitor of apoptosis 
repeat-containing 5 or BIRC5, is a protein that, in humans, is encoded 
by the BIRC5 gene. The survivin gene on chromosome 17q25 is now 
believed to consist of 4 dominant exons (1,2,3 AND 4) and 3 additional 
cryptic exons located either in intron 2(2alpha_, 2B) or intron 3(3B) 
and is required for cell division.11–12 It was demonstrated that the 
functions of survivin in cell division fall into three main categories: 
participation in chromosomal passenger protein biology, participation 
in the spindle checkpoint, and regulation of microtubule dynamics.13,14 
The ability of transformed cells to evade apoptosis and favor cell 
survival is a hallmark of tumor progression and resistance to therapy.14 
Understanding the multiple functional roles of survivin in cancer, 
including: resistance to cancer therapy, promoting angiogenesis and 
preventing cells from apoptosis makes this a relevant target protein 
for cancer biologists to comprehend.15
Survivin is also involved in the resistance of tumor cells to 
both chemotherapy and ionising irradiation, that’s why better 
understanding of survivin and its role in bladder cancer will help 
better understanding of the molecular biology of the disease and 
improvement of treatment.16–18 In this study we aim to investigate 
Survivin gene expression on both RNA and protein levels in urinary 
bladder tissue samples and Correlate between survivin expression and 
pathological prognostic parameters of patients with urinary bladder 
cancer risk.
Subjects and methods
Patients
All subjects were recruited from the Urology and Nephrology 
Center Mansoura University and Alexandria university hospital - 
Egypt. 
The present study was conducted on a total of 26 Egyptian 
individuals:
i. Different clinicopathological features were assessed among 
these patients 
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Abstract
Purpose: The aim of this study is to investigate the expression of survivin gene 
in patients suffering from urinary bladder cancer, thus contributing to further 
understanding of the molecular etiology of the disease by assessment of Survivin gene 
expression on both RNA and protein levels in urinary bladder tissue samples and 
Correlate between its expression and pathological prognostic parameters of patients 
with urinary bladder cancer risk. 
Methods: In the present study 26 cases of urinary bladder cancer and 26 cases of normal 
tissues far from tumor sites in the urinary bladder of the same patients (as control 
samples) were collected, also 10 paraffin-embedded tissue samples from consecutive 
of archival bladder specimens patients and 10 tissue samples that of healthy tissue 
from the same individual as control group were collected for immunohistochemical 
detection of survivin protein and real time PCR for survivin mRNA detection. 
Results: In normal tissues of control samples no expression for survivin gene has been 
noticed. However, in patients affected with bladder cancer the survivin expression was 
highly increased by increasing degree of tumor malignancy as indicated by real time 
PCR for survivin mRNA and immunohistochemistry for survivin protein.
Conclusion: From this study, it is concluded that survivin protein was not expressed 
in normal bladder urothelium but was present in a high percentage in tissue samples 
of patients suffering from bladder cancer and its expression is associated with disease 
recurrence, tumor grade, progression and mortality.
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ii. Samples that used to detect mRNA expression levels: Tissue 
samples were taken from tumor masses from urinary bladder 
tissues (26 tumor samples) and normal tissues far from tumor 
sites in the urinary bladder as control samples (26 control 
samples from the same patients) . All samples were stored at 
(-80°C) until they are used.
iii. Samples that used for protein expression detection: 10 
paraffin-embedded tissue samples from consecutive of archival 
bladder specimens patients, also 10 tissue samples that of 
healthy tissues from the same individuals as control group. 
Immunohistochemical staining for survivin was done 
using the procedure (According to: Buchwalow and 
Bocher, 2010) and Immunohistochemical staining 
protocol (Genemed, USA):
The list of reagents used for Immunohistochemical staining and 
mRNA extraction process could be found in (Table 1). 
Table 1 The list of reagents used in this study
Reagents for immunohistochemical staining for survivin protein Reagents for RNA extraction and cDNA synthesis used in real time PCR detection of survivin MRna
i. Formalin 10%.
ii. Different concentration of ethyl alcohol (30%, 50%, 70%, 80%, 90%, 95% 
and100%).
iii. Xylene .
iv. Paraffin wax.
v. Phosphate-buffered-saline (1XPBS) for 1 liter:
Dissolve 8 g of NaCl, 0.2g of KCl, 1.44g of Na2HPO4, and 0.24g of 
KH2PO4 in 800ml of distilled H2O. Adjust the PH to 7.4 with HCl, add 
H2O to 1 liter.
 vi. 10mM citrate buffer.
 vii. Mayer's Hematoxylin counters stain.
For immunohistochemistry staining:
I.  Primary antibody: Monoclonal murine Survivin Antibody NB500-238 
(novus, USA).
II.  Endogenous Peroxidase Blocking Solution-3% Hydrogen Peroxide.
III. Power-Stain TM 1.0 Poly HRP DAB Kit for Mouse+Rabbit (Genemed, 
USA) which includes:
i. Reagent A: One bottle of ready-to-use Poly HRP Conjugate for 
mouse + rabbit in an enzyme conjugate buffer containing stabilizing 
proteins and anti-microbial agents.
ii. Reagent B1: One bottle of 2X DAB chromogen solution.
iii. Reagent B2: One bottle of 2X DAB buffer solution.
1.  For RNA extraction:
i. Chloroform: isoamyl alcohol (49:1, v/v).
ii.  Ethanol.
iii.  Isopropanol.
iv.  Phenol.
v.  Sodium acetate (3 M, pH 4.0)
vi.  Solution D (denaturing solution)
a. 4M guanidinium thiocyanate (250g in 293ml of H2O) .
b. 25mM sodium citrate dihydrate
c. 0.5% (w/v) sodium lauryl sarcosinate (26.4 ml of10% (w/v). Add 
a magnetic bar and stir the solution on a combination heater-
stirrer at 65°C until all ingredients are dissolved. Store solution 
D at room temperature, and add 0.36 ml of 14.4 M stock beta 
mercaptoethanol per 50 ml of solution D just before use. 
Solution D may be stored for months at room temperature but 
is sensitive to light.
vii.   Polypropylene snap-cap tubes.
viii.  1.5ml microfuge tubes.
2. For cDNA synthesis:
I.  0.2 ml PCR tubes.
II.  Revert Aid First Strand cDNA Synthesis Kit(Thermo Scientific, 
Germany) Which includes:
For real time PCR Formulation of sequence-specific primers (according to 
Asanuma et al.19)
i. Survivin forward primer: 5΄AAG AAC TGG CCC TTC TTG GA 3΄
ii. Survivin reverse primer : 5΄CAA CCG GAC GAA TGC TTT T 3΄
iii. Survivin probe: 5΄ CCA GAT GAC GAC CCC ATA GAG GAA CA 
3΄ labeled by VIC® as a reporter dye on the 5´ end and TAMRA™ as 
a quencher dye on the 3´ end.
iv. TaqMan Universal PCR Master Mix (Applied Biosystems, USA).
The procedure included
i. Fixation of tissues in 10% neutral buffered formalin:
ii. Embedding each sample in a paraffin block: tissues after 
dehydration through different concentration of alcohol and 
clearing the tissues through 2 changes of xylene 1 hour each.
iii. Cutting and mounting the section at the desired thickness 
(usually 4-5 micrometer) on a microtome and float on a 40°C 
water bath containing sterile water, followed by transfer the 
section onto a slide and their Placement in 65°C oven for 30 
minutes.
iv. Deparaffinization and rehydration of tissue slides in 2 changes 
of xylene for 5 minutes each followed by Hydration of the 
slides.
v. Antigen retrieval must be done before immunohistochemical 
can proceed, this is due to formation of methylene bridges 
during fixation, which cross-link proteins and therefore mask 
antigenic sites antigen retrieval methods serve to break the 
methylene bridge and expose the antigenic sites in order to 
allow the antibody to bind.
The Immunohistochemical staining protocol (Genemed, USA) 
included:
The relation between survivin gene expression and urinary bladder cancer disease 28
Copyright:
©2017 Arafat et al.
Citation: Arafat W, Ashry MSE, Alrazek MAA, et al. The relation between survivin gene expression and urinary bladder cancer disease. Hos Pal Med Int Jnl. 
2017;1(2):26‒33. DOI: 10.15406/hpmij.2017.01.00007
i. Step 1: Endogenous Peroxidase Blocking.
ii. Step 2: Primary Antibody Incubation.
iii. Step 3: Poly horseradish peroxidase HRP Conjugate Incubation.
iv. Step 4: Adding Substrate to DAB Chromogen.
v. Step 5: Counterstaining with Hematoxylin.
vi. Step 6: Mountin and cover slip the specimen.
Detection of survivin mRNA expression by real-time 
PCR
 Procedure For RNA extraction from 26 tumor and 26 control tissues 
was done according to Chomczynski and Sacchi, 1987. This step was 
followed by cDNA synthesis and the reverse transcription reaction 
product can be directly used in PCR applications or stored at -20°C 
for less than one week. For longer storage, -70°C is recommended.
For real time PCR using TaqMan probes (Figure 1): According to 
Asanuma et al.19 quantitative RT-PCR was performed using a TaqMan 
Universal PCR Master Mix (Applied Biosystems, USA). The reaction 
mixture (50µl final volumes) contained 5µl of cDNA solution, 25µl 
of 2X Master Mix, 200nM forward and reverse primers, and 100 nM 
probe. The amplification cycles were 95°C for 15 seconds and 60°C 
for 1 min, and repeated for 40 cycles. The quantity of specific mRNA 
was normalized as a ratio to the amount of GAPDH, which was 
determined using TaqMan® GAPDH Control Reagents kit (Applied 
Biosystems, USA), according to manufacturers protocol.
Figure 1 TaqMan® probes mode of action.
Statistical methods 
The spss ANOVA was used to test the difference between 
normalized survivin values and disease-developing categories.
Results
Different clinicopathological features among studied 
population
In the studied group we assessed male to-female ratio, tumor grade, 
Pathologic Types, lymph node metastasis and tumor size according 
and stage of disease according to the TNM 2009 classification (Table 
2). However, the follow up of these patients to detect the survival and 
treatment outcome will be assessed in further future studies.
Table 2 The distribution of different Clinicopathological features among 
studied population
Clinicopathological features
Total (n=26)
No. %
Age
31-50 4 15.38%
51-70 19 73.07%
71-90 3 11.53%
Range
Mean
Median
S.D.
36-79
58.96
59
9.45
Sex
Male 22 84.61%
Female 4 15.38%
Mean 58.96
Median 59
S.D 9.45
Histological types
Adenocarcinoma 2 7.69
Transitional cell carcinoma 22 84.61
Small cell carcinoma 1 3.85
Squamous cell carcinoma 1 3.85
Grade
Grade I 5 19.23
Grade II 5 19.23
Grade III 16 61.54
Stage
Stage I 2 7.96
Stage II 8 30.77
Stage III 9 34.61
Stage IV 7 26.9
Size
< 5 10 38.5
5-10 13 50
> 10 3 11.5
Range
Mean
S.D.
1.5-12
6.67
2.6
Lymph node status
0 19 73.08
1 2 7.69
2 5 19.23
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Molecular results
Tissue expression of survivin mRNA quantitative survivin mRNA 
expression was measured in specimens excised from bladder cancer 
patients with varying stage and grade categories. In addition healthy 
tissue specimens from the same study individuals as a negative 
control group. RT-PCR analysis revealed sufficient expression in all 
cancer investigated samples. Representative data obtained in cancer 
specimens are shown in Figure 2.
Figure 2 Amplification curves of surviving mRNA extracted from bladder 
cancer patients. The last two curves indicated by black arrows are samples 
represent low expression of survivin gene.
All 26 tissue samples from bladder cancer patients were 
characterized by survivin mRNA expression. The spss ANOVA 
showed a significant correlation between survivin values and disease 
developing categories including: grade, stage, lymph node status and 
finally histological types (Table 3). However we have found that:
i. There is a significant positive correlation between the different 
Tumor grade and the relative expression of survivin mRNA in 
bladder cancer patients. P=0.021* indicating that the level of 
survivin mRNA might reflect the disease progression.
ii. There is a significant positive correlation between the different 
bladder cancer stages and the relative expression of survivin 
mRNA in bladder cancer patients. p=0.04* indicating that the 
level of survivin mRNA might reflect the disease progression.
iii. There is no significant positive correlation between the 
different lymph node status and the relative expression of 
survivin mRNA in bladder cancer patients. p=0.176.
iv. There is no significant positive correlation between the 
different histological types and the relative expression of 
survivin mRNA in bladder cancer patients. P=0.465.
Table 3 The correlation between survivin mRNA expression and different bladder cancer pathological characteristics
Characteristics No. %
Relative expression of surviving mRNA in bladder cancer patients
Mean Std. deviation Minimum Maximum
Grade
Grade1 5 19.23 64.492 54.93405 4.28 128
Grade2 5 19.23 641.648 975.6593 32 2352.53
Grade3 16 61.54 1684.398 1307.671 147.03 4096
F
p
4.581
0.021*
Stage
Early stage (I&II) 10 38.46 802.08 652.5 32 4096
Advanced stage (III & IV) 16 61.54 1403.78 865 4.28 4096
p 0.04*
Lymph node status
N0 19 73.08 894.8 1129.7 4.3 4096
N1 2 7.69 1806.6 772 1260.7 2352.5
N2 5 19.23 2141 1642.3 147 4096
F
p
1.802
0.176
Histological tumor types
Adenocarcinoma 2 7.69 384 181.0193 256 512
SCC 1 3.85 9.18 . 9.18 9.18
Small cell carcenoma 1 3.85 90.5 . 90.5 90.5
TCC 22 84.16 1346.063 1322.818 4.28 4096
Total 26 100 1172.349 1283.897 4.28 4096
F
p
0.883
0.465
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Immunohistochemical results (Table 4)
Table 4 The correlation between different bladder cancer grades and stages 
& survivin protein expression
Pathological 
features
Gene expression
Total
+ ++ +++
Grade
Grade
I
No 4 0 0 4
% 100.00% 0.00% 0.00% 40.00%
II
No 0 2 0 2
% 0.00% 100.00% 0.00% 20.00%
III
No 0 0 4 4
% 0.00% 0.00% 100.00% 40.00%
Total
No 4 2 4 10
% 100.00% 100.00% 100.00% 100.00%
P = 0.0001*
Stage
Stage
I
No 3 0 0 3
% 75.00% 0.00% 0.00% 30.00%
II
No 1 2 2 5
% 25.00% 100.00% 50.00% 50.00%
VI
No 0 0 2 2
% 0.00% 0.00% 50.00% 20.00%
Total
No 4 2 4 10
% 100.00% 100.00% 100.00% 100.00%
P=0.32
(From 10 paraffin-embedded tissue samples)
Survivin protein was overexpressed in urinary bladder cancer 
tissues. Positive or negative survivin overexpressed was determined 
by IHC staining. Cells that had positive survivin overexpression, 
revealed with brown nuclei, where cells that had negative survivin 
overexpression, revealed with blue nuclei. The intensity of the 
staining was designated as
i. Negative (0) if less than 10 % of the malignant cells were 
stained (Figure 3).
ii. Weak (+) if 10-50 % of the malignant cells were stained (Figure 
4).
iii. Moderate (+ +) if 50-80 % of the malignant cells were stained 
(Figure 5).
iv. Strong (+ + +) if over 80% of the malignant cells were stained 
(Figure 6).
The patient group could be divided into three subgroups according 
to protein expression levels: law (4 samples), moderate (2 samples) 
and high (4 samples). On the other hand all samples in the control 
group show negative IHC surviving staining.
Figure 3 Survivin negative immunostaining (X400).
Figure 4 Low grade survivin positive immunostaining some nuclei stained in 
brown color (blue arrow) due to the over expression of survivin protein inside 
these nuclei, the other nuclei stained blue (black arrows) as counterstaining 
(X400).
Figure 5 Intermediate grade survivin positive immunostaining many nuclei 
stained in brown color (blue arrow) due to the over expression of survivin 
protein inside these nuclei, the other nuclei stained blue (black arrows) as 
counterstaining (X400).
Figure 6 High grade survivin positive immunostaining most nuclei stained 
in brown color (blue arrow) due to the over expression of survivin protein 
inside these nuclei, some nuclei show mitosis (X400).
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Assessment of the correlation between different bladder cancer 
grades and stages & survivin protein expression revealed that: 
i. There is a significant positive correlation between the different 
Tumor grades and the protein expression level of survivin in 
bladder cancer Patients. P=0.0001*.
ii. There is no significant positive correlation between the different 
Tumor stages and the protein expression level of survivin in 
bladder cancer Patients. P=0.32.
Discussion
The present investigation was carried out on 26 patients with 
bladder cancer, the survivin protein expression in paraffin embedded 
tumor tissues were detected by immunohistochemical staining. 
Relative expression of survivin mRNA in fresh-frozen tumor tissues 
was detected by using Taq-Man probe real time PCR analysis. In the 
present study the ages of the bladder cancer patients ranged from 
36–79-years with means±SD 58.96±9.45 and median age 59 years.
This result is closely related to Zapatero et al.20 who reported a 
median age of 60 years (range 41-77) and Gupta et al.,21 study who 
found that the mean±SD age was 60.2±4.4 years old (range: 18–90 
years old). However, the median age of 63 years (range 42-75) was 
reported by Zietman et al.,22 and a median age of 63 years (range 31-
79) reported by Rodel et al.23
From the present study it was noticed that males were more 
affected than females, 22 males (84.61%) and 4 females (15.38%) this 
results is closely related to the previous results of the data reported 
by Tonoli et al.,24 where males represent 86% of the whole series and 
Gupta et al.21 who found that the male to female ratio was 8.6:1.21
From the present study it was noticed that the transitional cell 
carcinoma represented the great majority (22 cases constituting 
84.61%), adenocarcinoma (2 cases constituting 7.96%). While small 
cell carcinoma as well as squamous cell carcinoma each of them 
constituted 3.85% (1 case per each type). This is was similar to results 
reported by Lynch et al.3 who stated that most of the tumors 72.0% 
were transitional cell carcinomas and 22.0% were adenocarcinomas.3 
 From the present study it was noticed that most of the patients 
(16 patients, 61.54% ) had tumors with grade III ( 5 patients ,19.23 
%) had tumors with grade II, and (5 patients,19.23%) had grade I, 
However our data was close to Rodel et al.23 where high grade tumors 
represented 57.8% only,23 However, that was different from Zietman 
et al.20 who found that high grade tumors represent 77.7%, and also 
different from Zapatero et al.,22 who reported that 94% of the tumors 
were of high grade.20,22
The present study showed that 9 patients (34.61 %) had T3 disease, 
while T2 disease was seen in 8 patients (30.77%), 7patients (26.9%) 
had T4 disease and 2 patients (7.69%) with T1 disease stage, this 
result is consistent with the disease stage reported by Shariat et al.25 
who noticed that most of the patients (36,5%) had T3 disease, but 
different in the percent of other patient disease stages. However, this 
was different from the disease stage reported by Kaufman et al.26 
where T2 disease constituted 88% and T3 disease constituted 12% of 
the entire patient population.26 
The size of the bladder tumors among patients of the present 
study ranged from 1.5-12 cm with mean±SD 6.67 cm±2.6. half of the 
patients (50%) had tumors 5 - 10 cm in size, 38.5% had tumors 1- 5 
cm in size, and 11.5 % had tumors>10cm in size, on the other hand 
sabaa et al.,27 reported that most of the patients(73.01%) had tumors 
less than 3cm in size.27 In the present result it was noticed that there 
was 19 patients (73.07%) without nodal metastasis only 7 patients 
(26.9%) had variable degree of nodal metastasis. 
From the present study it was noticed that there is a positive 
significant correlation between survivin mRNA expression levels 
and tumor grade progression as follows: patients had GI disease had 
mean±SD expression level of 64.5±54.9.Patients with GII disease 
had mean±SD expression level of 461.64±975.65 and patients with 
GIII disease had mean±SD expression level of 1684.4±1307.67 with 
p value of 0.021. So there is a positive significant correlation between 
tumor grade progression and survivin expression level, so survivin 
expression increase disease progression. Higher levels of expression 
were associated with a reduced time to recurrence in noninvasive 
TCCs (p=0.027). On the other hand, Srivastava et al.28 noticed that 
survivin concentration did not show any association (p=0.349) with 
grade.28
According to the present study patients with early stage disease 
(stage I,II) had mean±SD survivin mRNA expression level of 
802.08±652.5 and patients with late stage disease (stage III,IV) had 
mean±SD survivin mRNA expression level of 1403.78±865,the p 
value=0.04 , so there is a significant positive correlation between 
survivin expression and disease stage progression, from this result 
we can conclude that increasing survivin expression may play a 
role in the progression of bladder cancer. This result is in consistent 
with the research results of Srivastava et al.28 noticed that survivin 
concentration showed direct and significant (p<0.001) correlation 
with stage, also our results is in agreement with the results of Weikert 
et al.29 who noticed that Survivin transcripts were commonly detected 
in tumor tissues, but not in normal urothelium, and increasing mRNA 
levels correlate with progressing pathologic stage (p=0.001) and 
grade categories (p<0.004). While the study of Shariat et al.18 showed 
a highly significant association of Survivin with muscle invasion as 
there study contain 726 patients in a multiinstitutional study.
The present study also showed that patients group without 
nodal metastasis (N0) had mean±SD survivin mRNA expression 
level of 894.8±1129.7, patients group with (N1) nodal metastasis 
had mean±SD survivin mRNA expression level of 1806.6±772 and 
patients group with (N2) nodal metastasis had mean±SD survivin 
mRNA expression level of 2141±1642.3, the p value=0.176, so there 
was no significant correlation between nodal metastasis and survivin 
expression in our patients group. On the other hand Shariat et al.,18 
noticed that survivin was expressed in 41 of 50 (82%) of the radical 
cystectomy specimens and 47 of 50 (94%) of the matched lymph 
node specimens., also they reported that the proportion of specimens 
with survivin expression increased from advanced TCC (64%) to 
cancerous lymph node tissue (94%). In patients who underwent radical 
cystectomy, survivin over-expression was significantly associated 
with advanced pathologic stage, metastases to lymph nodes, lympho-
vascular invasion, number positive lymph nodes, percent positive 
lymph nodes, disease recurrence, disease progression, and bladder 
cancer-specific mortality, also Srivastava et al. noticed that survivin 
concentration showed direct and significant (p<0.001) correlation 
with nodal status and cytology.
According to the present study patients suffering from 
adenocarcinoma had mean±SD survivin mRNA expression level of 
384±181.02, patients suffering from SCC had mean survivin mRNA 
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expression level of 9.18 without SD (one patient only), patients 
suffering from small cell carcinoma had mean survivin mRNA 
expression level of 90.5 without SD (one patient only) and patients 
suffering from TCC had mean±SD survivin mRNA expression level 
of 1346.06±1322.8, the p value of this relation was 0.465, so there was 
no significant correlation between pathological finding and survivin 
expression in our patients group.
According also to this study, immunohistochemical staining 
detecting survivin protein expression from 10 paraffin embedded 
tissues showed that; 4 patients had weak expression level (40%), 2 
had moderate level (20%) while the remaining 4 samples showed 
high expression level (40%). On the other hand all samples in control 
group showed negative IHC survivin staining. 
According to the level of protein expression by 
immunohistochemical staining, 4 patients with weak staining (100%)
had grade 1 disease, 2 patients with moderate level( 100%) had grade 
2 and the all 4 with high level of protein expression (100%) had grade 
3, indicating that there is a positive correlation between survivin 
protein expression level and tumor grades p=0.0001. 
According also to protein expression; 3 patients with weak 
staining (75%) had stage1 while the remaining one (25%) had stage 
2. The 2 patients with moderate protein expression level (100%) had 
stage 2. Finally 2out of 4 patients with high staining level (50%) had 
stage 2 while the remaining 2 in this group had stage 3, indicating 
that there is no correlation between surviving gene protein expression 
and different tumor stages. p=0.32. this is somehow different from 
Weikert et al.29 that showed from the quantitative data that survivin 
expression increases with both the stage and grade of bladder TCC. 
They demonstrated a higher expression level in invasive superficial 
TCC (pT1) than in the noninvasive type (pTa). These findings suggest 
that survivin may influence the malignant potential of transformed 
transitional cells and may thus play a role in the progression of 
bladder cancer.30
 In the original report by Swana et al.31 (where expression of 
survivin was determined by immunohistochemistry, no detectable 
survivin was reported in normal transitional cells, but it was present 
in 78% of tumoral specimens.
Recommendation
Further molecular studies should be addressed to elucidate the 
relation of survivin gene expression and mechanisms of apoptosis 
and cell division, especially in bladder cancer, as well as that of other 
molecular markers may help to diagnose patients most likely to benefit 
from the mode of treatment. Also, from this study we do believe that 
detection of survivin mRNA by real time PCR is more important than 
immunohistochemical studies.
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